AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Predictive Markers for Dasatinib to Treat Solid Tumors

Technology Benefits: Predicts efficacy and response of dasatinib therapy on triple negative breast cancer subtypes Genes expressed in patients with specific breast cancer subtypes may be sensitive to therapy with SRC kinase inhibitors Predictive markers may be used in clinical development of compounds to treat solid tumors

Technology Application: Use markers to identify individuals who are likely to respond, or are responsive, to therapy with dasatinib or other SRC kinase inhibitors Predict response of dasatinib to treat the triple negative subset of women with breast cancer

Detailed Technology Description: UCLA researchers have identified predictive markers to identify human breast cancer cells that are likely to respond to dasatinib or to therapy with another SRC kinase inhibitor. This unique gene set has been identified by using an in vitro pharmocogenomic approach.

Supplementary Information: Patent Number: US8007995B2
Application Number: US200893042A
Inventor: Finn, Richard S. | Dering, Judy | Slamon, Dennis J. | Ginther, Charles L. | Clark, Edwin A.
Priority Date: 10 Nov 2005
Priority Number: US8007995B2
Application Date: 29 Oct 2008
Publication Date: 30 Aug 2011
IPC Current: C12Q000100 | C12Q000168 | G01N003353 | G01N0033574
US Class: 435004 | 43500611 | 4350071 | 43500721 | 43500723 | 435006
Assignee Applicant: Bristol-Myers Squibb Company,Princeton | The Regents of the University of California
Title: Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
Usefulness: Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
Summary: The method is useful for determining the responsiveness of a mammalian tumor cell or an individual with cancer, where the tumor cell is a breast cell. The breast cell is basal cell, luminal cell, mesenchymal cell, breast cancer associated gene-1 (BRCA-1) cell, cell that has undergone an epithelial to mesenchymal transition, or cell that reduced expression of an estrogen, progesterone, and herceptin (HER)-2 receptor. The cancer is breast cancer. The tumor is a breast cancer tumor. The method (M1) is useful for treating an individual suffering from cancer (all claimed).
Novelty: Detecting tumor cell responsiveness to treatment with specific thiazolecarboxamide compound, involves determining expression level of a gene chosen from moesin, caveolin-1 or yes-associated protein-1 in tumor cell

Industry: Disease Diagnostic/Treatment

Sub Category: Cancer/Tumor

Application No.: 8007995

Others

State of Development

Inventors have employed the approach in human breast cancer cell lines in vitro. These markers will need to be validated in a clinical setting.

Background

Cancer is one of the leading causes of death worldwide, killing millions of people every year. Of the different types of cancers, breast cancer is the leading cause of death among women, affecting over one million women worldwide every year. Currently, dasatinib is approved to treat chronic myeloid leukemia (CML) and is in development to treat solid tumors, including breast cancer. However, there is a need to be able to identify patients most likely to respond to drugs like dasatinib. New diagnostics methods will be especially useful for women whose breast cancers fall under a specific triple negative subtype (estrogen receptor negative, progesterone receptor negative, and HER2 negative), and therefore lack effective treatments. Due to the lack of effective treatments, there is a need to identify the patients that might benefit from dasatinib.

Related Materials

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. (2007)

Additional Technologies by these Inventors

Tech ID/UC Case

20277/2006-263-0

Related Cases

2006-263-0

*Abstract: Investigators at the UCLA Geffen School of Medicine have identified potential markers to predict the response of breast cancer patients to dasatinib, an oral multi-kinase SRC/ABL inhibitor. There is potential to use these markers in the clinical development of dasatinib and other SRC kinase inhibitors that treat solid tumors.

*IP Issue Date: Aug 30, 2011

*Principal Investigator: Name: Edwin Clark
Department:

Name: Judy Dering
Department:

Name: Richard Finn
Department:

Name: Charles Ginther
Department:

Name: Dennis Slamon
Department:

Country/Region: USA

For more information, please click Here